Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 5/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20576395 | 0.86 | APP (0.49) | RAB9ASMN1; SMN2APPFFAR1MAOB | |
| SCHEMBL11647126 | 0.84 | APP (0.56) | RAB9ASMN1; SMN2APPFFAR1KDM4E | |
| SCHEMBL31375355 | 0.84 | APP (0.56) | RAB9ASMN1; SMN2APPFFAR1KDM4E | |
| SCHEMBL7898169 | 0.82 | RAB9A (0.59) | RAB9ASMN1; SMN2PTPN1MAOBMAPK1 | |
| SCHEMBL30835101 | 0.82 | RAB9A (0.59) | RAB9ASMN1; SMN2PTPN1MAOBMAPK1 | |
| SCHEMBL28843836 | 0.82 | FFAR1 (0.59) | APPFFAR1MAPTMAPK1TDP1 | |
| SCHEMBL528926 | 0.81 | RAB9A (0.61) | RAB9ASMN1; SMN2PTPN1KDM4EHPGD | |
| SCHEMBL7778474 | 0.81 | MAOB (0.59) | RAB9ASMN1; SMN2PTPN1MAOBMAPT | |
| SCHEMBL8982918 | 0.81 | RAB9A (0.57) | RAB9ASMN1; SMN2PTPN1KDM4EHPGD | |
| SCHEMBL1021663 | 0.80 | CCR5 (0.48) | RAB9AAPPFFAR1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112661681-A | Polymerizable compound | 默克专利股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-9938229-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-20160032189-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160032189-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, ILK, LCP1 | RAB9A 579/4885SMN1; SMN2 2420/4885APP 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.